Taken together with the reduction of HbA1c and the increase of both insulin sensitivity and β-cell function, the results of this study clearly justified the efficacy and safety of PIO in both lean and obese Chinese type 2 diabetes patients. The gene discussed is INS; the disease is type 2 diabetes mellitus.